Compare LAB & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAB | AURA |
|---|---|---|
| Founded | 1999 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 354.1M | 419.5M |
| IPO Year | 2008 | 2021 |
| Metric | LAB | AURA |
|---|---|---|
| Price | $0.88 | $6.82 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $1.35 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 1.8M | 276.9K |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.54 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $101,937,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.63 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.87 | $4.73 |
| 52 Week High | $1.72 | $7.48 |
| Indicator | LAB | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 33.67 | 61.88 |
| Support Level | N/A | $5.94 |
| Resistance Level | $1.39 | $7.04 |
| Average True Range (ATR) | 0.05 | 0.35 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 10.80 | 71.59 |
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.